3SBio Inc. (TRSBF)

Market Cap	5.72B -37.2%
Revenue (ttm)	2.53B +94.3%
Net Income	1.21B +305.8%
EPS	0.49 +303.6%
Shares Out	n/a
PE Ratio	4.71
Forward PE	13.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Open	2.200
Previous Close	2.150
Day's Range	2.150 - 2.200
52-Week Range	2.000 - 4.740
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About 3SBio

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 6,109
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error